Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms [Seeking Alpha]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Seeking Alpha
SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts. SYRE's $757M cash position funds operations into H2 2028, supporting multiple clinical milestones and reducing near-term financing risk. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Rasi Bhadramani/iStock via Getty Images The last time I wrote about Spyre Therapeutics, Inc. ( SYRE ) it was in a Seeking Alpha article entitled " Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting ." With More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on See
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) had its price target raised by Stifel Nicolaus from $70.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 [Yahoo! Finance]Yahoo! Finance
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026GlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 3/5/26 - Form EFFECT
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SYRE's page on the SEC website